Pharmacogenetics overhyped, says UK Royal Society

The field of pharmacogenetics has been overhyped and is still more than a decade away from living up to its promise in clinical practice, largely due to shortages in researchers and lack of international coordination, according to a recent report from the UK's Royal Society.

Written byStephen Pincock
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

The field of pharmacogenetics has been overhyped and is still more than a decade away from living up to its promise in clinical practice, largely due to shortages in researchers and lack of international coordination, according to a recent report from the UK's Royal Society.

"When the human genome was sequenced, I think that – not unreasonably – the press and some of the scientists themselves gave the impression it was going to change medicine practically overnight," says David Weatherall, chair of the working group that wrote the report. Overall, the report suggests that it will be another 15 to 20 years before the use of medicines tailored to individual genotypes is widespread. "Personalized medicines show promise but they have undoubtedly been overhyped," Weatherall says.

Ian Hall, from the University of Nottingham, disagrees, suggesting the impact of pharmacogenetics on clinical medicine would be felt more quickly. "I think that 10–15 ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies